866-997-4948(US-Canada Toll Free)

Gaucher Disease Type III - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 36 Pages

Gaucher Disease Type III - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gaucher Disease Type III Pipeline Review, H2 2016, provides an overview of the Gaucher Disease Type III (Genetic Disorders) pipeline landscape.

Gaucher disease type III also known as chronic neuronopathic Gaucher disease (subacute form of neuronopathic Gaucher disease). Symptoms include mental deterioration, ataxia, and myoclonic seizures. The cause of Gaucher disease III is the accumulation of a fatty material called glucocerebroside (also known as glucosylceramide) Treatment includes enzyme replacement therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gaucher Disease Type III Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gaucher Disease Type III (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gaucher Disease Type III (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gaucher Disease Type III and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 1 and 1 respectively.

Gaucher Disease Type III (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gaucher Disease Type III (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Gaucher Disease Type III (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gaucher Disease Type III (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gaucher Disease Type III (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gaucher Disease Type III (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gaucher Disease Type III (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gaucher Disease Type III (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gaucher Disease Type III Overview 6
Therapeutics Development 7
Pipeline Products for Gaucher Disease Type III - Overview 7
Gaucher Disease Type III - Therapeutics under Development by Companies 8
Gaucher Disease Type III - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Gaucher Disease Type III - Products under Development by Companies 11
Gaucher Disease Type III - Companies Involved in Therapeutics Development 12
Actelion Ltd 12
Belrose Pharma Inc 13
Erad Therapeutics Inc 14
Genzyme Corp 15
Shire Plc 16
Gaucher Disease Type III - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ambroxol - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ibiglustat - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
miglustat - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Recombinant Protein for Type I and Type III Gaucher's Disease - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
velaglucerase alfa - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Gaucher Disease Type III - Dormant Projects 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36

List of Tables
Number of Products under Development for Gaucher Disease Type III, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Gaucher Disease Type III - Pipeline by Actelion Ltd, H2 2016 12
Gaucher Disease Type III - Pipeline by Belrose Pharma Inc, H2 2016 13
Gaucher Disease Type III - Pipeline by Erad Therapeutics Inc, H2 2016 14
Gaucher Disease Type III - Pipeline by Genzyme Corp, H2 2016 15
Gaucher Disease Type III - Pipeline by Shire Plc, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Gaucher Disease Type III - Dormant Projects, H2 2016 34

List of Figures
Number of Products under Development for Gaucher Disease Type III, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Targets, H2 2016 18
Number of Products by Stage and Targets, H2 2016 18
Number of Products by Mechanism of Actions, H2 2016 20
Number of Products by Stage and Mechanism of Actions, H2 2016 20
Number of Products by Routes of Administration, H2 2016 22
Number of Products by Stage and Routes of Administration, H2 2016 22
Number of Products by Molecule Types, H2 2016 24
Number of Products by Stage and Molecule Types, H2 2016 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *